Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06628908 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Site details revised at 1 of 76 sitesv21
  2. Site details revised at 1 of 76 sitesv20
  3. Site details revised at 1 of 76 sitesv19
  4. Site details revised at 1 of 76 sitesv18
  5. Eligibility criteria shortened, about 11 words Secondary endpoints revised (2) · Site details revised at 1 of 76 sitesv17 Show 2 more changesShow less
    • Secondary endpoints revised (2)
    • Site details revised at 1 of 76 sites

    See this version in full on ClinicalTrials.gov ↗

Show 15 earlier versionsHide 15 earlier versions
  1. Study sites revised (76)v16 See this version in full on ClinicalTrials.gov ↗
  2. Site details revised at 1 of 76 sitesv15
  3. Study sites: 75 to 76v14
  4. Site details revised at 1 of 75 sitesv13
  5. Study sites: 74 to 75v12
  6. Study sites: 73 to 74v11
  7. Study sites: 71 to 73v10
  8. Study sites: 70 to 71v9
  9. Study sites: 58 to 70 Primary and study completion dates: May 2027 to May 31, 2027v8 Show 1 more changeShow less
    • Primary and study completion dates: May 2027 to May 31, 2027
  10. Study sites: 23 to 58v7
  11. Study sites: 17 to 23v6
  12. Study sites: 14 to 17v5
  13. Study sites: 13 to 14v4
  14. Study sites: 10 to 13v3
  15. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 10 · Start date changed from estimate of Oct 2024 to Oct 1, 2024v2 Show 2 more changesShow less
    • Study sites: 0 to 10
    • Start date changed from estimate of Oct 2024 to Oct 1, 2024
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Suzetrigine (SUZ) in participants with pain associated with diabetic peripheral neuropathy (DPN).
Trial Details
NCT Number NCT06628908
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Diabetic Peripheral Neuropathic Pain
Enrollment 1,100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov